STAT· @statnews · X·· 20 天前精选AI 评分80
AI 导读
礼来在研药物retatrutide在一项大型糖尿病研究中,降血糖和减重效果均优于诺和诺德的Ozempic。报道同时指出,该药的长期安全性仍存疑问,更多细节见原文链接。
推荐理由
一项大型糖尿病研究显示,礼来在研药物retatrutide在降糖和减重上优于Ozempic,但长期安全性仍存疑问。
正文
In a large diabetes study, Eli Lilly's investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic.
However, questions remain about long-term safety. More details here: https://trib.al/D0cRVjm
来源:STAT · x.com